Tyrosine kinase inhibitor (TKIs)
TKI post-HSCT- MRD+Ph+ALL-2018
Phase 3 small_molecule active
Quick answer
Tyrosine kinase inhibitor (TKIs) for Philadelphia Chromosome Positive Acute Lymphocytic Leukemia is a Phase 3 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active